Introduction de Novacyt sur NYSE Alternext

Back

Paris – 12 October 2012– NYSE Euronext (NYX) today announced the listing on NYSE Alternext in Paris of Novacyt, a specialist in next-generation cytology solutions.

Founded in 2006, Novacyt designs, develops and markets innovative liquid-based cytology solutions with applications in molecular biology. The company’s NovaPrep® Processor System uses fully patented technology to optimise detection of precancerous and cancerous lesions. Novacyt is present in France and on international markets through a network of 13 distributors. Its products carry the EC-IVD label in Europe and the SFDA label in China, and it has received a marketing authorisation for Russia.

Novacyt (ticker: ALNOV) was listed through admission to trading of 2,389,335 existing shares and 318,127 new shares issuedunder a Global Offering.[1] The Global Offering raised a total of €2.6 million, with theadmission and issue price of shares set at €8.10 per share. Market capitalisation stood at around €22 million on the day of listing.

“We are delighted to welcome Novacyt to NYSE Alternext, where listing will enable it to pursue development of new products to help detect cancers in a variety of countries,” said Marc Lefèvre, Head of European Business Development and Client Coverage at NYSE Euronext. “Backed by our trading platform and very wide network of members, NYSE Alternext – our market designed especially for small and mid-size companies – offers both listed companies and investors access to a unique pool of liquidity.”

Eric Peltier, Chairman and CEO of Novacyt added: “We would like to thank all our shareholders for their trust, which has enabled us to take this major step. They will now be able to accompany us as our R&D programmes develop new products to round out our existing range and improve cancer detection and diagnostics.”

In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their marketcapitalisation totals €6 billion. Today 183 companies are listed on NYSE Alternext.


[1]The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

 

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway and Portugal.
As of September 2025, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal host over 1,700 listed issuers with €6.5 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices.
In November 2025, Euronext successfully acquired a majority stake in the Athens Stock Exchange (ATHEX), further expanding its footprint and strengthening its pan-European market infrastructure.

For the latest news and resources, please visit the Media Centre. 
Follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.